US 12,011,560 B2
Drug delivery methods and systems
Zita S. Netzel, Los Altos, CA (US); Gary Stacey, Cambridge (GB); Alexander David Norman, Trumpington (GB); Congyi Huang, Cambridge (GB); Timothy Charles Frearson, Hartley Wintney (GB); Charles Frazer Kilby, St. Neots (GB); Patrick H. Ruane, Dublin, CA (US); Alan J. Levy, Bellevue, WA (US); Kevin W. Gelston, Moraga, CA (US); Jennifer Darmour, Seattle, WA (US); Jenny E. Hapgood, Tacoma, WA (US); David Evans Roth, Issaquah, WA (US); Ronald A. Overbeck, Winthrop, WA (US); and Ling-Kang Tong, Hayward, CA (US)
Assigned to Morningside Venture Investments Limited, Monaco (MC)
Filed by Morningside Venture Investments Limited, Monaco (MC)
Filed on Jul. 28, 2022, as Appl. No. 17/815,879.
Application 15/699,382 is a division of application No. 15/009,683, filed on Jan. 28, 2016, granted, now 10,213,586, issued on Feb. 26, 2019.
Application 17/815,879 is a continuation of application No. 16/284,933, filed on Feb. 25, 2019, granted, now 11,400,266.
Application 16/284,933 is a continuation of application No. 15/699,382, filed on Sep. 8, 2017, granted, now 10,232,156, issued on Mar. 19, 2019.
Claims priority of provisional application 62/263,516, filed on Dec. 4, 2015.
Claims priority of provisional application 62/132,436, filed on Mar. 12, 2015.
Claims priority of provisional application 62/108,959, filed on Jan. 28, 2015.
Prior Publication US 2023/0191097 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 35/00 (2006.01); A61M 5/142 (2006.01); A61M 5/145 (2006.01); A61M 5/168 (2006.01)
CPC A61M 35/00 (2013.01) [A61M 5/14244 (2013.01); A61M 5/14248 (2013.01); A61M 5/145 (2013.01); A61M 5/1456 (2013.01); A61M 5/16877 (2013.01); A61M 5/16881 (2013.01); A61M 2005/14268 (2013.01); A61M 2005/14506 (2013.01); A61M 2005/14573 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A two-part bioactive agent delivery system, the system comprising:
a disposable part comprising:
a bioactive agent reservoir, the bioactive agent reservoir comprising an agent reservoir piston movable relative to the bioactive agent reservoir,
a bolus chamber, the bolus chamber comprising a bolus piston movable relative to the bolus chamber, the volume of the bolus chamber being less than the volume of the bioactive agent reservoir,
an agent outlet in fluid communication with a transdermal membrane, and
a valve having a first position communicating the bioactive agent reservoir with the bolus chamber and a second position communicating the bolus chamber with the agent outlet; and
a reusable part comprising a valve driver, a power source and control electronics, the control electronics being adapted to control the valve driver to actuate the valve to move to the first position or to the second position to deliver bioactive agent from the bioactive agent reservoir to the agent outlet; and
an agent reservoir loading component extending between the agent reservoir piston and the reusable part, the loading component configured to apply force to the agent reservoir piston to enable the valve to release a dose of bioactive agent from the bioactive agent reservoir to the bolus chamber when the disposable part is connected to the reusable part.